萬泰生物(603392.SH):鼻噴流感病毒載體新冠肺炎疫苗進入二期臨牀試驗
格隆匯12月31日丨萬泰生物(603392.SH)宣佈,公司與廈門大學、香港大學合作研發的鼻噴流感病毒載體新冠肺炎疫苗,已進入二期臨牀試驗,二期臨牀試驗由江蘇省疾病預防控制中心負責實施,該試驗已經獲得江蘇省疾病預防控制中心倫理委員會批准啟動。
該產品系重組新型冠狀病毒RBD基因的減毒流感病毒株接種MDCK細胞,經培養、收穫病毒液並純化後,加適宜穩定劑製成,為無色到微乳白色澄明液體。接種該產品後,可刺激機體產生抗新型冠狀病毒的免疫力,用於預防新冠肺炎。
截至2020年12月31日,現階段公司針對該疫苗的研發投入為人民幣4852.91萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.